Skip to main content
Search
Main content
Alzheimer's & dementia : the journal of the Alzheimer's Association
Published

Exploring longitudinal relationships among Alzheimer's disease biomarkers

Authors

Benjamin Saef, Kellen K Petersen, Katherine Volluz, Yan Li, Duygu Tosun, Marta Mila-Aloma, Leslie M Shaw, Henrik Zetterberg, Jeffrey L Dage, Carrie E Rubel, Kyle Ferber, Lei Du-Cuny, Janaky Coomaraswamy, Michael Baratta, Yulia Mordashova, Ziad S Saad, Gallen Triana-Baltzer, Nicholas J Ashton, Emily A Meyers, Erin G Rosenbaugh, J Martin Sabandal, Anthony W Bannon, William Z Potter, Alzheimer's Disease Neuroimaging Initiative (ADNI), Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer's Disease Project Team, Suzanne E Schindler

Abstract

Alzheimers Dement. 2026 Aug;22(8):e71711. doi: 10.1002/alz.71711.

ABSTRACT

INTRODUCTION: While most studies of Alzheimer's disease (AD) examine cross-sectional relationships among biomarkers, longitudinal relationships are also highly relevant.

METHODS: This study in the Alzheimer's Disease Neuroimaging Initiative cohort (n = 373) used non-parametric Spearman correlations to explore the relationships of baseline values and rates of change in plasma biomarkers and rates of change in key AD outcomes.

RESULTS: Compared to rates of change of plasma biomarkers, baseline values of plasma biomarkers were more strongly associated with rates of change in key AD outcomes. Change in amyloid positron emission tomography (PET) was most strongly associated with baseline values of amyloid beta (Aβ)42/Aβ40 and phosphorylated tau (p-tau)217, especially in amyloid PET--negative individuals. Changes in cortical thickness and measures of cognition were most strongly associated with baseline p-tau217, especially in amyloid PET-positive individuals.

DISCUSSION: Baseline p-tau217 is associated with rates of change of amyloid pathology and cognition. Visualization tools were developed to enable researchers to explore AD biomarker relationships.

PMID:42535261 | DOI:10.1002/alz.71711

UK DRI Authors

Prof Henrik Zetterberg

Group Leader

Pioneering the development of fluid biomarkers for dementia

Prof Henrik Zetterberg